South Korea's Han All Pharmaceutical Co Ltd said on Thursday it would make a 26-for-100 rights issue in November to raise operating funds. The issue will increase paid-in capital to 15 billion won from 11.27 billion. A Han All statement said the company plans to issue 745,757 new common shares, of which 20 percent would be offered to its employees. The rest will be offered to shareholders registered as of October 11.